Logo

As Expected, Transgenomic Closes $15M Private Placement of Common Stock

Oct 31, 2005

NEW YORK, Oct. 31 (GenomeWeb News) - Transgenomic has completed its private placement of common stock to a group of institutional investors led by Lehman Brothers, the company said today.

 

As GenomeWeb News  previously reported, the transaction was originally priced at $1.01 per share for 15 million shares. Acompany spokesperson confirmed the final amount today as "rounded off to approximately $15 million."

 

Net proceeds from the sale were used to repay the company's debt of approximately $8.6 million with Laurus Master Fund. The remainder was retained for working capital.

 

The Omaha-Neb.-based company has committed to preparing and filing a registration statement covering the resale within 30 days of closing.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.